WeLeader Biomedical recently released its 2025 fiscal report, showcasing a remarkable "triple increase" in its gross margin, operating margin, and net profit margin. The company reported annual revenue of NT$1.109 billion (+11.92% YoY) and a record-breaking net profit of NT$209 million (+22.53% YoY), with an annual EPS of $4.64.

The board has proposed a cash dividend of NT$4.1, representing a high payout ratio of 88.36%. Based on the February 26 closing price of $69.9, this translates to an attractive dividend yield of 5.87%.

WeLeader Biomedical’s growth is primarily attributed to two structural drivers:

1. Stable Diagnostic Demand: As the government lowers the age for adult preventive health screenings and introduces new test items, the demand for primary care testing reagents continues to rise steadily.
2. Digital Integration: The successful implementation of the Laboratory Information System (LIS) has transitioned the company from a simple reagent supplier to a high-value medical IT service provider, significantly enhancing customer stickiness and operational margins.

Looking ahead to 2026, the company remains cautiously optimistic. By deepening the integration of In-Vitro Diagnostics (IVD) with medical information services, WeLeader Biomedical aims to further optimize its profit structure and solidify its position within the healthcare ecosystem.

Resource: 威力德2025營運 三率三升